Description
T1DM is associated with diminished quality of life, substantial healthcare costs, as well as increased morbidity and mortality risk. In 2020, there were an estimated 240,000 emergency department visits in the United States due to diabetic ketoacidosis (DKA), and approximately 25% of T1DM are diagnosed while hospitalized for DKA.
With the emergence of screening techniques and therapeutics to delay the onset of T1DM, this program aims to educate clinicians on how to evaluate all aspects of screening, including when to screen, who to screen, how to screen, how to interpret screening results, and treatment and monitoring steps following screening.
This program will cover the following micro-lessons (5-7 minutes each):
- Why, When, Who and How to Screen
- Interpreting Screening Results
- Clinical Treatment and Management Following Screening
- Preventing Hospitalization for Diabetic Ketoacidosis through Monitoring with Diabetes Technology (including light intro to diabetes tech in T1D)
Target Audience
The target audience for this program includes endocrinologists, pediatricians, and primary care providers who provide care to patients with and at risk for type 1 diabetes.
Learning Objectives
1. Evaluate common clinician screening questions including when to screen, who to screen, how to screen, and how to interpret results.
2. Assess methods to prevent diabetic ketoacidosis in both at risk individuals and patients with type 1 diabetes (screening and advanced technology).
Accreditation Statement
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.
AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.
Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 0.5 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org
Faculty and Disclosures
Alex Tuttle, MD, MEd
Division of Pediatric Diabetes and Endocrinology, Department of Pediatrics
Indiana University School of Medicine
Riita Veijola, MD, PhD
Professor, Chief Physician, Department of Pediatrics
University of Oulu and Oulu University Hospital
STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.
DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Riita Veijola, MD, PhD: Advisory Board Member, Sanofi.
The following faculty reported no relevant financial relationships: Alex Tuttle, MD, MEd
The following committee member who planned and reviewed content for this activity reported the following financial relationships:
Milay Luis Lam, MD: The Obesity Society, member, chair of the Clinical Management Section, no payment
speaker for Sanofi, educational non product promotion.
The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.
The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.
Acknowledgement of Commercial Support:
This educational activity is supported by an educational grant from Abbott.